سعر ايكسوسيريليك 500 مجم 20 قرص 2024

Ursodeoxycholic acid 500 mg film-coated tablets (Gypto Pharma, Egypt), 2 strips x 10 white oblong biconvex tablets scored on one side.

• Dissolution of radiolucent (non-radio-opaque) cholesterol gallstones not larger than 15 mm in diameter in patients with a functioning gall bladder.Gypto Pharma (Egyptian manufacturer)
• Treatment of primary biliary cholangitis (PBC) without decompensated cirrhosis.Health Products Regulatory Authority (HPRA), Ireland
• Hepatobiliary disorders associated with cystic fibrosis in children aged 6 to 18 years.Population: Children 6-18 yearsHealth Products Regulatory Authority (HPRA), Ireland

• Common: soft stools or diarrhoea. Very rare: severe right upper abdominal pain (PBC), calcification of gallstones, decompensation of cirrhosis (advanced PBC), urticaria. Not known: nausea, vomiting, pruritus.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland

• Acute inflammation of the gall bladder or biliary tract; biliary tract occlusion; frequent biliary colic; radio-opaque calcified gallstones; impaired gall bladder contractility; hypersensitivity to bile acids or excipients.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland

• Monitor AST, ALT and GGT every 4 weeks for the first 3 months, then every 3 months; in advanced PBC, rare hepatic decompensation has occurred; women treated for gallstones should use effective non-hormonal contraception; reduce dose for diarrhoea and stop if persistent.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland

• Colestyramine, colestipol, aluminium hydroxide or smectite antacidsBind UDCA in the gut; separate administration by at least 2 hours.Health Products Regulatory Authority (HPRA), Ireland
• CiclosporinUDCA can affect ciclosporin absorption; monitor levels and adjust dose.Health Products Regulatory Authority (HPRA), Ireland
• Oestrogens, clofibrateIncrease biliary cholesterol secretion and may counteract gallstone dissolution.Health Products Regulatory Authority (HPRA), Ireland

• Limited human data; animal studies showed reproductive toxicity in early gestation; must not be used during pregnancy unless clearly necessary; exclude pregnancy before starting.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland
• Milk levels of UDCA are very low in the few documented cases; adverse reactions in breastfed infants are probably not expected.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland

• Ursodeoxycholic acid: Reduces cholesterol saturation of bile by inhibiting intestinal cholesterol absorption and decreasing biliary cholesterol secretion, allowing gradual dissolution of cholesterol gallstones; in cholestatic liver disease replaces toxic lipophilic bile acids with hydrophilic cytoprotective UDCA (Irish Ursofalk SmPC).